Human IgG1 Fc Protein 4674

Additional Information:
accession P01857|express systemHEK293|product tagNo Tag|purity> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC|backgroundIgG1 is most abundant in serum among the four IgG subclasses (IgG1, 2, 3 and 4) and binds to Fc receptors (FcR) on phagocytic cells with high affinity. Fc fragment is demonstrated to mediate phagocytosis, trIgGer inflammation, and target Ig to particular tissues.IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.|molecular weightThe protein has a predicted MW of 25.5 kDa. Due to glycosylation, the protein migrates to 31-33 kDa based on Tris-Bis PAGE result.|available size100 g, 500 g|endotoxinLess than 1EU per g by the LAL method.|Human IgG1 Fc Protein 4674proteinSize and concentration100, 500g and lyophilizedFormLyophilizedStorage InstructionsValid for 12 months from date of receipt when stored at -80C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.Storage bufferShipped at ambient temperature.Purity> 95% as determined by Tris-Bis PAGEtarget relevanceIgG1 is most abundant in serum among the four IgG subclasses (IgG1, 2, 3 and 4) and binds to Fc receptors (FcR) on phagocytic cells with high affinity. Fc fragment is demonstrated to mediate phagocytosis, trIgGer inflammation, and target Ig to particular tissues.IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.Protein namesImmunoglobulin heavy constant gamma 1 (Ig gamma-1 chain C region) (Ig gamma-1 chain C region EU) (Ig gamma-1 chain C region KOL) (Ig gamma-1 chain C region NIE)Gene namesIGHG1,IGHG1Mass9606DaFunctionConstant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trIgGer the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268). Mediates IgG effector functions on monocytes trIgGering ADCC of virus-infected cells.Subellular location[Isoform 1]: Secreted .; [Isoform 2]: Cell membrane ; Single-pass membrane protein .StructureImmunoglobulins are composed of two identical heavy chains and two identical light chains; disulfide-linked (PubMed:20176268). Interacts with FCGR1A; this interaction mediates IgG effector functions on monocytes. Interacts with FCGR2A and FCGR3A (PubMed:11711607).Post-translational modificationGlycosylation on Asn-180 is required for interaction with Fc receptors and ability to activate the complement pathway.; (Microbial infection) Deglycosylation on Asn-180 by S.pyogenes EndoS or Endos2 endoglucosidases prevents interaction between immunoglobulin-gamma (IgG) and Fc receptors, impairing ability to activate the complement pathway.Target Relevance information above includes information from UniProt accession: P01857The UniProt Consortium|